ovarian metastases of breast cancer were found in 40 patients (23.5%). Multivariate analyses revealed that younger ages (OR, 0.94; 95% CI, 0.88 to 0.99; $p=0.04$) and the number of sites of metastasis at surgery (≥ 3 sites; OR, 3.99; 95% CI, 1.37 to 11.59; $p=0.01$) were significantly related with breast cancer ovarian metastases. The remaining studied characteristics were not statistically significant.

Conclusions Younger ages and having 3 or more sites of metastases at surgery appears to be risk factors for ovarian implants in previously metastatic breast cancer patients.

EPV024/#508

ADENOID CYSTIC CARCINOMA OF THE BREAST IN MEXICAN POPULATION: EXPERIENCE OF 12 YEARS A CENTER OF CONCENTRATION

¹G Moreno*, ²DA Maciel Roman, ²V Bautista Pina, ²JA Tenorio Torres, ²F Villegas Carlos. ¹National Cancer Institute, Mexico, Gynecology Oncology, Tlalpan, Mexico; ²Breast Disease Institute, Surgery, Coyoacán, Mexico

10.1136/ijgc-2021-IGCS.91

Objectives Describe the presentation characteristics of ACC in the Mexican population at the Breast Disease Institute from 2007 to 2019.

Methods Observational, descriptive, case series, of Breast Disease Institute FUCAM[®] patients.

Results A case series was recorded with 9 patients with ACC (table 1), representing 0.5% of our breast cancer cases. With an average age of presentation of 63 years. Grade III was presented in 66.6%. The mean tumor size was 4.8 cm, while the mean tumor size in the surgical specimen was 2.5 cm, in 88.8% in early stages. All with triple negative breast cancer (TNBC) (table 2), one case (5%) with lymph node involvement with Axillary lymph node dissection (ALND). In a case of Breast conserving surgery (BCS) with Intraoperative radiation therapy (IORT) with Intrabreast, two cases with modified radical mastectomy (MRM), 66% with total mastectomy (MT) and sentinel node biopsy (SLNB). In 55% of the cases, adjuvant chemotherapy taxane-based. While 44.4% were indicated radiotherapy, with an average disease-free period of 63 months.

Conclusions So we consider that our contribution can answer some questions of ACC in the population Mexican. We present our 12-year institutional experience with 9 cases. Our

Abstract EPV024/#508 Table 1 Characteristics of patients

Case	Age at Diagnosis (years)	Histology	Grade	Pattern	cT (cm)	pT (cm)	Clinical stage AJCC	Pathological stage AJCC
1	43	ACC	III	Basaloid	9	5.1	IIB(T3)	IIB
2	49	ACC	III	Cribiform	11	1.1	IA	IA
3	72	ACC	I	Cribiform	2.8	2.3	IIA	IIA
4	51	ACC	I	0	2	3.5	IIA	IIA
5	72	ACC + DCIS	III	Multifocal	2	1.7	IIB	IIA
6	77	ACC	I	Invasive	2	3	IIA	IIA
7	60	ACC	III	Invasive	1.5	1	IB	IB
8	56	ACC	III	Cribiform	3.5	3	IIA	IIA
9	60	ACC	III	Invasive	3	3	IIA	IIA
Mean	63				4.8	2.5		

ACC: adenoid cystic carcinoma, DCIS: ductal carcinoma in situ, AJCC: American Joint Committee on Cancer.

Abstract EPV024/#508 Table 2 Treatment in the ACC

	TNBC	Ki 67	Surgery	Lymph nodes	Nodes with metastases	Adjuvant chemotherapy	Adjuvant radiotherapy
1	YES	20%	MRM	15	0	YES	YES
2	YES	10%	BCS + SLNB + IORT	2	0	YES	INTRABREAST
3	YES	25%	MT + SLNB	2	0	NO	0
4	YES	20%	MT + SLNB	1	0	YES	NO
5	YES	70%	MRM	22	3	YES	YES
6	YES	3%	MT + SLNB + ALND	15	0	NO	0
7	YES	0%	MT + SLNB	3	0	NO	0
8	YES	40%	MT + SLNB	4	0	NO	0
9	YES	0%	MT + SLNB	8	0	YES	YES

TNBC: triple negative breast cancer, MRM: modified radical mastectomy, BCS: Breast conserving surgery, SLNB: sentinel node biopsy, MT: mastectomy, IORT: Intraoperative radiation therapy (IORT), ALND: Axillary lymph node dissection (ALND).

results are similar to the published series, however there is controversy for treatment with adjuvant.

EPV025/#546

CLINICAL-PATHOLOGICAL FEATURES AND TREATMENT MODALITIES IN DCIS WITH MICROINVASION: A TUNISIAN EXPERIENCE

¹S Slim*, ²H Bouaziz, ³R Ben Romdhane, ³I Marghli, ⁴S Kammoun, ⁵M Driss, ²R Chargui, ⁶K Rahal. ¹Salah Azaiez Institut of Oncology, Tunis, Surgical Oncology, Tunis, Tunisia; ²Salah Azaiez Institute of Oncology, Surgical Oncology, Tunis, Tunisia; ³Salah Azaiez Institut of Oncology, Tunis, Surgical Oncology Department, Tunis, Tunisia; ⁴Salah Azaiez Institute of Oncology, Department of Pathology, Tunis, Tunisia; ⁵Salah Azaiez Institute, Surgical Oncology, Monastir, Tunisia; ⁶Salah Azaiez Institute of Cancerology, Surgical Oncology, Tunis, Tunisia

10.1136/ijgc-2021-IGCS.92

Objectives Ductal carcinoma in situ with microinvasion (DCISM) is rare, < 1% of all breast cancer cases. The histological definition of this entity remains controversial. Due to the inconsistent definition and limited data regarding this breast cancer subtype, there are no clear treatment recommendations.

Methods We retrospectively reviewed the clinical-pathological aspects, the treatments, and followed by a cohort of 17 patients diagnosed with DCISM and microinvasive carcinoma from 2000 to 2017 in our institution.

Results The median age was 52 years old, 58.8% of patients were menopausal, all patients were operated on, 42.2% had conservative treatment, sentinel lymph node dissection was performed in 64.7% of cases with no micro or macro-metastases. Pathological examination found DCISM in 47% of cases (53% of cases were pure microinvasive ductal carcinoma). Comedonecrosis was found in only two cases. Hormonal receptors were positives in 87.9% of DCISM cases. We performed radiotherapy in 47% of patients. Adjuvant chemotherapy was prescribed to 17.6% of patients, and 70.6% of patients underwent adjuvant endocrine therapy. Only one case underwent targeted adjuvant therapy. The Median follow-up was 42 months. We did not notice any relapse or metastasis.

Conclusions The development of screening programs increases the diagnosis of small tumors, especially DCISM. This entity remains with a good prognosis. Better knowledge and evaluation of risk factors of relapse are needed to define adjuvant treatment.